



UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

| SERIAL NUMBER FILING DATE | FIRST NAMED APPLICANT | ATTORNEY DOCKETT NO. |
|--|---|--|
| | | |
| | | EXAMINER |
| | | |
| | | ART UNIT PAPER NUMBER |
| | | 24 |
| FYAMIN | DATE MA ER INTERVIEW SUMMARY RECORD | ILED: |
| All participants (applicant, applicant's representative, PTO p | | • |
| n 171. | 15.1 | 2 |
| | | |
| (2) E. Mata | (4) | |
| Date of Interview 4/24/96 | · | |
| Type: ☐ Telephonic St. Personal (copy is given to ☐ a | applicant applicant's representative). | |
| Exhibit shown or demonstration conducted: Yes No | | |
| | | |
| Claims discussed: All Claims Identification of prior art discussed: All C | cited prior ard. | |
| Description of the general nature of what was agreed to if an Submitted proposed an Submitted proposed an Submitted proposed an Submitted proposed and Submitted | A | , · |
| of the daims | | |
| (A fuller description, if necessary, and a copy of the amenda attached. Also, where no copy of the amendments which we | | |
| 1. It is not necessary for applicant to provide a separat | te record of the substance of the interview. | |
| Unless the paragraph below has been checked to indicate to WAIVED AND MUST INCLUDE THE SUBSTANCE OF THE action has already been filed, then applicant is given one mo | INTERVIEW (e.g., items 1-7 on the reverse side of | this form). If a response to the last Office |
| 2. Since the examiner's interview summary above (increquirements that may be present in the last Office response requirements of the last Office action. Approx 1 above is also checked. | cluding any attachments) reflects a complete respons action, and since the claims are now allowable, this copplicant is not relieved from providing a separate reco | completed form is considered to fulfill the |

PROPOSED CLAIMS FOR UMMC91-03A (U.S.S.N. 08/009,833)

Cancel Claims 1, 2, 4, 7-14, 17-18, and 22-24.

Claims 19-21 are unchanged:

- 19. A method of immunizing a vertebrate against influenza virus, said method comprising administering to a vertebrate a DNA transcription unit comprising DNA encoding an influenza virus antigen operatively linked to a promoter region, thereby eliciting a humoral immune response, a cell-mediated immune response or both, against the influenza virus antigen, whereby the vertebrate is protected from disease caused by influenza virus.
- 20. The method of Claim 19, wherein the influenza virus antigen is hemagglutinin.
- 21. The method of Claim 20, wherein the hemagglutinin is subtype H1 or H7.

NEW CLAIMS: Previous claims 2 and 7-10 are cancelled and rewritten as dependent on Claim 19.

- 25. The method of Claim 19, wherein the DNA transcription unit is of nonretroviral origin.
- 26. The method of Claim 19, wherein the vertebrate is a mammal.
- 27. The method of Claim 26, wherein the mammal is a human.
- 28. The method of Claim 19, wherein the DNA transcription unit, in a physiologically acceptable carrier, is administered to a vertebrate through a route of administration chosen from the group consisting of intranasal, intravenous, intramuscular, intraperitoneal, intradermal and subcutaneous.

807